Table 2.
Baseline Characteristics Between mRS 2–6 and mRS 0–1 at Discharge Group in Patients Treated with IV tPA
| Overall (n=102) | mRS 2–6 (n=75) | mRS 0–1 (n=27) | P-value | |
|---|---|---|---|---|
| Age (mean (SD)) | 64.01 (13.02) | 63.31 (12.94) | 65.96 (13.29) | 0.37 |
| Male, n (%) | 67 (65.69) | 50 (66.67) | 17 (62.96) | 0.73 |
| DNT time (median [IQR]) | 47.50 [35.00–64.00] | 48.00 [35.00–64.00] | 44.00 [35.50–68.50] | 0.99 |
| Time from symptom onset to IV-tPA, min (median [IQR]) | 174.50 [136.50–228.25] | 186.00 [149.00–229.50] | 160.00 [115.50–217.50] | 0.11 |
| Bridging mechanical thrombectomy, n (%) | 34 (33.33) | 31 (41.33) | 3 (11.11) | 0.01 |
| Pre-mRS score (%) | 0.91 | |||
| 0 | 81 (79.41) | 58 (77.33) | 23 (85.19) | |
| 1 | 8 (7.84) | 6 (8.00) | 2 (7.41) | |
| 2 | 6 (5.88) | 5 (6.67) | 1 (3.70) | |
| 3 | 4 (3.92) | 3 (4.00) | 1 (3.70) | |
| 4 | 2 (1.96) | 2 (2.67) | 0 (0.00) | |
| 5 | 1 (0.98) | 1 (1.33) | 0 (0.00) | |
| Admission NIHSS score (median [IQR]) | 9.00 [4.00–12.75] | 9.00 [5.00–14.00] | 6.00 [3.00–10.50] | 0.04 |
| Admission NIHSS score ≤5 (%) | 33 (32.35) | 22 (29.33) | 11 (40.74) | 0.28 |
| Hypertension, n (%) | 67 (65.69) | 48 (64.00) | 19 (70.37) | 0.55 |
| Atrial fibrillation, n (%) | 19 (18.63) | 13 (17.33) | 6 (22.22) | 0.58 |
| Diabetes mellitus, n (%) | 30 (29.41) | 23 (30.67) | 7 (25.93) | 0.64 |
| Hyperlipidemia, n (%) | 14 (13.73) | 10 (13.33) | 4 (14.81) | 1 |
| Prior stroke, n (%) | 27 (26.47) | 21 (28.00) | 6 (22.22) | 0.56 |
| Coronary artery disease, n (%) | 18 (17.65) | 12 (16.00) | 6 (22.22) | 0.67 |
| Prior antiplatelet therapy, n (%) | 20 (19.61) | 15 (20.00) | 5 (18.52) | 0.87 |
| Prior statin therapy, n (%) | 15 (14.71) | 12 (16.00) | 3 (11.11) | 0.77 |
| Smoking, n (%) | 59 (57.84) | 41 (54.67) | 18 (66.67) | 0.28 |
| Drinking, n (%) | 44 (43.14) | 31 (41.33) | 13 (48.15) | 0.54 |
| TOAST, n (%) | 0.29 | |||
| LAA | 67 (65.69) | 50 (66.67) | 17 (62.96) | |
| CE | 26 (25.49) | 18 (24.00) | 8 (29.63) | |
| SAA | 2 (1.96) | 2 (2.67) | 0 (0.00) | |
| Other | 4 (3.92) | 4 (5.33) | 0 (0.00) | |
| Unknown | 3 (2.94) | 1 (1.33) | 2 (7.41) | |
| Admission SBP level, mmHg (median [IQR]) | 144.00 [130.00–162.00] | 141.50 [129.25–161.00] | 145.00 [139.50–158.50] | 0.44 |
| Admission DBP level, mmHg (median [IQR]) | 82.50 [75.00–93.00] | 81.00 [75.00–93.00] | 86.00 [76.00–91.50] | 0.96 |
| Admission serum glucose level, mmol/L (median [IQR]) | 6.80 [5.55–8.50] | 6.95 [5.88–8.80] | 5.70 [5.05–7.35] | 0.07 |
| HbA1c level, % (median [IQR]) | 6.10 [5.80–6.60] | 6.20 [5.85–6.85] | 6.00 [5.75–6.30] | 0.24 |
| LDL level, mmol/L (mean (SD)) | 2.50 (0.86) | 2.42 (0.80) | 2.71 (0.97) | 0.16 |
| Cholesterol level, mmol/L (mean (SD)) | 4.11 (0.94) | 4.03 (0.93) | 4.33 (0.96) | 0.20 |
| CT hypointensity sign, n (%) | 22 (21.57) | 18 (24.00) | 4 (14.81) | 0.32 |
| MCA hyperintensity sign, n (%) | 9 (8.82) | 7 (9.33) | 2 (7.41) | 1 |
| Fazekas scale (median [IQR]) | 1.00 [1.00–2.00] | 1.00 [1.00–2.00] | 1.00 [1.00–1.00] | 0.94 |
| Large vessel occlusion, n (%) | 32 (31.37) | 28 (37.33) | 4 (14.81) | 0.03 |
| sICH-NINDS, n (%) | 9 (8.82) | 9 (12.00) | 0 (0.00) | 0.14 |
| sICH-SITS, n (%) | 4 (3.92) | 4 (5.33) | 0 (0.00) | 0.52 |
| NLR at 0 h, 10^9/L (median [IQR]) | 4.15 [3.08–6.49] | 4.35 [3.42–7.02] | 3.41 [2.60–5.03] | 0.03 |
| NLR at 24 h, 10^9/L (median [IQR]) | 4.77 [3.27–9.32] | 5.87 [3.84–10.65] | 3.11 [2.52–4.52] | 0.01 |
| NLR at 48 h, 10^9/L (median [IQR]) | 4.92 [2.76– 7.19] | 5.72 [3.59–8.14] | 2.62 [2.20–4.48] | <0.001 |
| NLR at discharge, 10^9/L (median [IQR]) | 3.92 [2.68–5.40] | 4.43 [3.08–5.89] | 2.57 [2.13–3.92] | <0.001 |
| LMR at 0 h, 10^9/L (median [IQR]) | 4.15 [3.02–5.82] | 4.57 [3.13–5.89] | 3.81 [2.89–5.28] | 0.38 |
| LMR at 24 h, 10^9/L (median [IQR]) | 2.74 [1.98–3.84] | 2.52 [1.80–3.54] | 3.45 [2.69–4.92] | 0.01 |
| LMR at 48 h, 10^9/L (median [IQR]) | 2.60 [1.91–3.82] | 2.18 [1.75–3.23] | 3.70 [2.66–4.31] | <0.001 |
| LMR at discharge, 10^9/L (median [IQR]) | 2.88 [2.32–3.66] | 2.88 [2.28–3.51] | 2.96 [2.75–4.91] | 0.10 |
| NLR change between 0 h and 24 h, 10^9/L (median [IQR]) | 0.68 [−0.45–2.53] | 1.22 [−0.27–3.27] | −0.10 [−0.83–0.82] | 0.01 |
| NLR change between 24 h and 48 h, 10^9/L (median [IQR]) | −0.35 [−2.47–0.36] | −0.40 [−2.71–0.55] | −0.34 [−1.41–0.05] | 0.99 |
| NLR change between 0 h and discharge, 10^9/L (median [IQR]) | −0.61 [−2.09–0.91] | −0.54 [−2.09–1.45] | −0.85 [−2.23–0.48] | 0.60 |
| NLR change between 48 h and discharge, 10^9/L (median [IQR]) | −0.75 [−2.46–0.91] | −0.83 [−2.94–0.99] | −0.15 [−0.90–0.56] | 0.13 |
| LMR change between 0 h and 24 h (median [IQR]) | −1.25 [−3.11–−0.01] | −1.33 [−3.40–−0.65] | −0.27 [−1.22–0.27] | 0.01 |
| LMR change between 24 h and 48 h, 10^9/L (median [IQR]) | −0.08 [−0.74–0.35] | −0.02 [−0.66–0.35] | −0.19 [−0.82–0.23] | 0.58 |
| LMR change between 0 h and discharge, 10^9/L (median [IQR]) | −1.29 [−2.75–0.02] | −1.45 [−3.00–−0.35] | −0.35 [−1.88–0.33] | 0.03 |
| LMR change between 48 h and discharge, 10^9/L (median [IQR]) | 0.16 [−0.56–1.07] | 0.47 [−0.36–1.37] | −0.20 [−1.03–0.48] | 0.01 |
Abbreviations: DNT, door-to-needle; IV, intravenous thrombolysis; tPA, tissue plasminogen activator; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; TOAST, Trial of Org 10172 in Acute Stroke Treatment; LAA, large atherosclerosis artery; CE, cardiac embolism; SAA, small artery occlusion; SBP, systolic blood pressure; DBP, diastolic blood pressure; LDL, low density lipoprotein; MCA, middle cerebral artery; sICH, symptomatic intracerebral hemorrhage; NINDS, National Institute of Neurological Disorders and Stroke trial; SITS, Safe Implementation of Thrombolysis in Stroke; NLR, neutrophil-to-lymphocyte ratio; LMR, lymphocyte-to-monocyte ratio.